The JUPITER Trial: Myth or Reality?

Forecasting the Future of Cardiovascular Disease in the United States

(2011) Paul A. Heidenreich et al.   CIRCULATION

The Cost-Effectiveness of Rosuvastatin Therapy

(2011) Mark Hlatky   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels

(2011) Niteesh K. Choudhry et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study

(2011) Heart Protection Study Collaborative Group   LANCET

The JUPITER Trial: Responding to the Critics

(2010) Paul M. Ridker et al.   AMERICAN JOURNAL OF CARDIOLOGY

Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)

(2010) Paul M. Ridker et al.   AMERICAN JOURNAL OF CARDIOLOGY

Statins and All-Cause Mortality in High-Risk Primary Prevention

(2010) Kausik K. Ray   ARCHIVES OF INTERNAL MEDICINE

By Jove! What Is a Clinician to Make of JUPITER?

(2010) Sanjay Kaul   ARCHIVES OF INTERNAL MEDICINE

Cholesterol Lowering, Cardiovascular Diseases, and the Rosuvastatin-JUPITER Controversy

(2010) Michel de Lorgeril   ARCHIVES OF INTERNAL MEDICINE

Stopping Randomized Trials Early for Benefit and Estimation of Treatment EffectsSystematic Review and Meta-regression Analysis

(2010) Dirk Bassler   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary

(2010) Philip Greenland et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

(2009) John J.V. McMurray et al.   CIRCULATION

From Here to JUPITER

(2009) Erica S. Spatz et al.  

The JUPITER Trial

(2009) Paul M Ridker  

Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein

(2009) Paul M Ridker et al.  

Prevalence of Low Low-Density Lipoprotein Cholesterol With Elevated High Sensitivity C-Reactive Protein in the U.S.

(2009) Erin D. Michos et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lipid lowering for primary prevention

(2009) Salim Yusuf et al.   LANCET

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

(2009) Paul M Ridker et al.   LANCET

Early stopping of randomized clinical trials for overt efficacy is problematic

(2008) Dirk Bassler et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments

(2008) Edward J. Mills et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Perioperative β blockers in patients having non-cardiac surgery: a meta-analysis

(2008) Sripal Bangalore et al.   LANCET

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial

(2008)   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE